9IMR image
Deposition Date 2024-07-04
Release Date 2025-07-09
Last Version Date 2025-07-09
Entry Detail
PDB ID:
9IMR
Keywords:
Title:
Crystal structure of geranylgeranyl pyrophosphate synthase Rv0562 from Mycobacterium tuberculosis in complex with IPP
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
1.89 Å
R-Value Free:
0.19
R-Value Work:
0.14
R-Value Observed:
0.14
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Nonaprenyl diphosphate synthase
Gene (Uniprot):grcC1
Chain IDs:A, B
Chain Length:335
Number of Molecules:2
Biological Source:Mycobacterium tuberculosis H37Rv
Primary Citation
Structural insight of a bi-functional isoprenyl diphosphate synthase Rv0562 from Mycobacterium tuberculosis.
Int.J.Biol.Macromol. ? 145171 145171 (2025)
PMID: 40513738 DOI: 10.1016/j.ijbiomac.2025.145171

Abstact

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis. Mtb uses MK-9(II-H2), which consists of an isoprenyl side chain containing nine isoprene units, with one being hydrogenated in the β-position, as an essential element in the electron transport system. Rv0562 that can operate geranylgeranyl diphosphate synthase (GGPPs) activity catalyzes the synthesis of MK-9(II-H2) by condensing one molecule of DMAPP with eight molecules of isopentenyl diphosphate (IPP) to form a C45 long-chain isoprenoid product. In this study, the structures of Rv0562 were determined in the apo-form at a resolution of 2.54 Å and in complex with IPP and Mg2+ at a resolution of 1.89 Å, revealing detailed interactions between the enzyme and substrates. Moreover, the crystal structure of the Rv0562-DM variant was determined at 2.27 Å resolution in complex with polyethylene glycol (PEG), which occupies the substrate binding tunnel, mimicking the long-chain product. The chain length determination mechanism of Rv0562 is also probed through mutagenesis experiments. The obtained structures help us understand how Rv0562 catalyzes isoprenyl chain elongation, showing implications in developing new anti-Mtb treatments.

Legend

Protein

Chemical

Disease

Primary Citation of related structures